An interventional study of Standard Triple Therapy and Experimental: Standard Triple Therapy Plus Fluoroquinolone in Opportunistic Infections, HIV Related and Disseminated Mycobacterium Avium Complex Infection, sponsored by Shanghai Public Health Clinical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Shanghai Public Health Clinical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background:
Disseminated Mycobacterium avium complex (MAC) infection remains a serious opportunistic infection in patients with advanced HIV infection, particularly among those with severe immunosuppression. Despite the widespread use of antiretroviral therapy (ART), disseminated MAC (DMAC) continues to be associated with significant morbidity and mortality. The current standard treatment consists of a macrolide-based triple regimen, including a macrolide, ethambutol, and rifamycin. However, in patients with high mycobacterial burden or profound immunodeficiency, early microbiological response and clinical improvement are often suboptimal, and treatment is complicated by drug interactions and tolerability issues.
Objective:
This study aims to evaluate whether adding a fluoroquinolone (levofloxacin or moxifloxacin) to the standard triple therapy improves early clinical outcomes in HIV-infected patients with disseminated MAC infection.
Methods:
This is a prospective, multicenter, randomized, open-label, controlled trial. A total of 124 adult HIV-infected patients with confirmed disseminated MAC infection will be randomly assigned in a 1:1 ratio to receive either standard triple therapy (macrolide, ethambutol, and rifamycin) or an intensified four-drug regimen with the addition of a fluoroquinolone during the initial 8-week intensive phase. Participants will be followed for at least 24 weeks.
Outcomes:
The primary endpoint is the clinical symptom resolution rate at Day 28. Secondary endpoints include microbiological outcomes (culture or molecular conversion at Days 28, 56, and 84), time to culture conversion, mortality, relapse, and safety outcomes including adverse events and QT interval prolongation.
Significance:
This study will provide prospective evidence on whether an intensified treatment strategy can improve early clinical response and microbiological clearance in disseminated MAC infection, while maintaining an acceptable safety profile. The findings may help optimize treatment strategies for HIV-associated disseminated MAC infection.
Background and Rationale:
Disseminated Mycobacterium avium complex (MAC) infection remains a major opportunistic infection in patients with advanced HIV infection, particularly among those with severe immunosuppression (e.g., CD4 \<50 cells/μL). Although the incidence of disseminated MAC (DMAC) has declined in the era of antiretroviral therapy (ART), it continues to pose a substantial clinical burden due to delayed diagnosis, high mycobacterial load, and frequent co-infections. Clinically, DMAC often presents with systemic symptoms such as fever, weight loss, anemia, and multi-organ involvement, including bone marrow, liver, spleen, and lymph nodes.
Current guidelines recommend a macrolide-based triple therapy consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (typically rifabutin). This regimen has demonstrated efficacy in reducing mortality and preventing macrolide resistance. However, in real-world clinical practice, early microbiological clearance and symptom improvement remain suboptimal, particularly in patients with high disease burden or delayed immune reconstitution. In addition, drug-drug interactions, especially with ART, and tolerability issues may limit treatment effectiveness.
Fluoroquinolones have demonstrated in vitro activity against mycobacteria and possess favorable pharmacokinetic properties, including good tissue penetration. Retrospective studies suggest that the addition of a fluoroquinolone to standard regimens may improve outcomes in disseminated MAC infection, but high-quality prospective evidence is lacking. Therefore, an intensified treatment strategy incorporating a fluoroquinolone during the early phase of therapy may enhance bacterial clearance and improve clinical outcomes.
Study Objectives:
The primary objective of this study is to determine whether adding a fluoroquinolone (levofloxacin or moxifloxacin) to standard triple therapy improves clinical symptom resolution at Day 28 in HIV-infected patients with disseminated MAC infection.
Secondary objectives include evaluating microbiological outcomes (culture or molecular conversion), time to culture conversion, mortality, relapse, treatment failure, and safety outcomes, including adverse events and QT interval prolongation.
Study Design:
This is a prospective, multicenter, randomized, open-label, controlled clinical trial. A total of 124 eligible adult participants with confirmed disseminated MAC infection will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.
Control group: Standard triple therapy consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and rifabutin (or an equivalent rifamycin-based regimen according to local practice).
Experimental group: Standard triple therapy plus a fluoroquinolone (levofloxacin or moxifloxacin), administered during the initial 8-week intensive phase.
The choice of fluoroquinolone will be determined at baseline based on clinical considerations such as renal function and risk of QT interval prolongation, and will remain fixed during the intensive phase unless safety concerns necessitate modification.
Treatment and Follow-up:
Participants will receive study treatment according to group assignment, with ART initiated or continued as per standard clinical practice, typically within 2 weeks after starting anti-MAC therapy. Patients will be followed for at least 24 weeks, with scheduled visits at baseline and predefined time points (e.g., Days 7, 14, 28, 56, and 84, and Weeks 24 and beyond).
Clinical assessments will include symptom evaluation, physical examination, laboratory tests, and safety monitoring. Microbiological assessments will include culture and/or molecular testing from blood or other sterile sites, with emphasis on consistent sampling sources across time points.
Outcome Measures:
The primary endpoint is the proportion of participants achieving clinical symptom resolution at Day 28, defined by sustained defervescence, improvement in symptom scores, stabilization or gain in body weight, absence of treatment escalation, and survival.
Secondary endpoints include:
Microbiological conversion rates at Days 28, 56, and 84 Time to culture conversion All-cause and MAC-related mortality Relapse and treatment failure rates Safety outcomes, including adverse events (graded by CTCAE), serious adverse events, and QT interval changes
Safety Considerations:
Fluoroquinolones are associated with potential adverse effects, including QT interval prolongation, tendon disorders, and central nervous system toxicity. Therefore, baseline and periodic electrocardiogram monitoring will be performed, along with electrolyte assessment and careful evaluation of concomitant medications. Predefined criteria for dose adjustment or discontinuation will be applied to ensure participant safety.
Significance:
This study aims to generate high-quality prospective evidence on whether an intensified four-drug regimen can improve early clinical and microbiological outcomes in disseminated MAC infection without compromising safety. The results may inform future treatment guidelines and optimize management strategies for HIV-associated disseminated MAC infection.
167 studies on the registry are indexed under AIDS-Related Opportunistic Infections; 2 are open to participants now.
This study's planned enrollment of 124 is above the median of 100 across 95 interventional studies indexed under AIDS-Related Opportunistic Infections.
Browse AIDS-Related Opportunistic Infections studies →Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive standard triple therapy for disseminated Mycobacterium avium complex infection, consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and rifabutin. Antiretroviral therapy is continued or initiated according to standard clinical practice and drug-drug interaction assessment.
Drug: Standard Triple Therapy
Participants receive standard triple therapy for disseminated Mycobacterium avium complex infection, consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and rifabutin, plus a fluoroquinolone (levofloxacin or moxifloxacin) during the initial 8-week intensive phase. The fluoroquinolone is selected at baseline based on clinical considerations and is intended to remain unchanged during the intensive phase unless modification is required for safety reasons. Antiretroviral therapy is continued or initiated according to standard clinical practice and drug-drug interaction assessment.
Drug: Experimental: Standard Triple Therapy Plus Fluoroquinolone
Standard triple therapy for disseminated MAC infection consisting of a macrolide, ethambutol, and rifabutin, administered according to protocol-defined dosing and duration.
Also known as: Azithromycin, Clarithromycin, Ethambutol, Rifabutin
Drug page: AzithromycinStudies of AzithromycinAzithromycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants receive standard therapy for disseminated Mycobacterium avium complex infection plus a fluoroquinolone during the initial 8-week intensive phase.
Also known as: Azithromycin, Ethambutol, Rifabutin, Levofloxacin, Moxifloxacin, clarithromycin
Clinical Symptom Resolution Rate at Day 28
The proportion of participants achieving clinical symptom resolution at Day 28. Clinical symptom resolution is defined as meeting all of the following criteria: 1. absence of fever for at least 48 hours without the use of antipyretics; 2. improvement in systemic symptoms, defined as a ≥50% reduction in total symptom score or all individual symptom scores ≤1; 3. stabilization or increase in body weight compared with baseline; 4. no requirement for escalation or modification of antimycobacterial therapy due to disease progression; 5. survival through Day 28. Participants who do not meet all criteria, require rescue therapy, or die before Day 28 are classified as non-responders.
Time frame: Day 28 (±3 days)
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices), will be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Beginning 6 months and ending 5 years following article publication.
Start is estimated for Apr 2026; primary completion for Dec 2028, 32 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azithromycin
AIDS-Related Opportunistic Infections →
Shanghai Public Health Clinical Center